L'hypertension artérielle masquée chez les diabétiques de type 2 : Prévalence, facteurs associés et retentissement cardiovasculaire

Hadjkacem, F.; Triki, Faten; Frikha, Hamdi; Charfeddine, S.; Boujelbene, Khouloud; Ghorbel, Dorra; Kammoun, S.; Abid, M.

doi:10.1016/j.ancard.2021.10.018

Cited by 8 publications

(9 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Meanwhile, the prevalence of LV hypertrophy, as measured by echocardiography, in asymptomatic patients with T2D is high, 51 and routine screening for patients with T2D who are asymptomatic for CVD is not recommended at this time, provided atherosclerotic CVD risk factors are treated as per the 2023 ADA guidelines. 52 Hadjkacem et al 53 reviewed the value of assessing masked arterial hypertension (HTN). Masked HTN (MHTN) is associated with CVD risk, a risk that is similar to that of permanent HTN and is common in patients with T2D.…”

Section: The Importance Of Monitoring Cardiorenal Risk In Patients Wi...mentioning

confidence: 99%

See 1 more Smart Citation

Management of the ‘wicked’ combination of heart failure and chronic kidney disease in the patient with diabetes

Bell

McGill

Jerkins³

2023

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

Patients with type 2 diabetes are at an increased risk of developing heart failure and chronic kidney disease. The presence of these co‐morbidities substantially increases the risk of morbidity as well as mortality in patients with diabetes. The clinical focus has historically centred around reducing the risk of cardiovascular disease by targeting hyperglycaemia, hyperlipidaemia and hypertension. Nonetheless, patients with type 2 diabetes who have well‐controlled blood glucose, blood pressure and lipid levels may still go on to develop heart failure, kidney disease or both. Major diabetes and cardiovascular societies are now recommending the use of treatments such as sodium‐glucose co‐transporter‐2 inhibitors and non‐steroidal mineralocorticoid receptor antagonists, in addition to currently recommended therapies, to promote cardiorenal protection through alternative pathways as early as possible in individuals with diabetes and cardiorenal manifestations. This review examines the most recent recommendations for managing the risk of cardiorenal progression in patients with type 2 diabetes.

show abstract

Section: The Importance Of Monitoring Cardiorenal Risk In Patients Wi...mentioning

confidence: 99%

“…Hadjkacem et al 53 reviewed the value of assessing masked arterial hypertension (HTN). Masked HTN (MHTN) is associated with CVD risk, a risk that is similar to that of permanent HTN and is common in patients with T2D.…”

Section: The Importance Of Monitoring Cardiorenal Risk In Patients Wi...mentioning

confidence: 99%

Management of the ‘wicked’ combination of heart failure and chronic kidney disease in the patient with diabetes

Bell

McGill

Jerkins³

2023

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

“…Traditional clinical risk factors, such as glycemic control and blood pressure management, have been valuable in assessing DN risk, but they often lack the sensitivity and specificity needed for early detection. 4,5 In recent years, there has been a growing interest in exploring the potential of incorporating specific biomarkers into predictive models to enhance the accuracy of DN risk assessment. In particular, integrated biomarker prediction models have made substantial strides in improving risk assessment and prognosis in various medical conditions, such as cardiovascular disease, 6 cancer, 7 and renal disorders.…”

Section: Introductionmentioning

confidence: 99%

Machine Learning-Based Predictive Modeling of Diabetic Nephropathy in Type 2 Diabetes Using Integrated Biomarkers: A Single-Center Retrospective Study

Zhu,

Zhang,

Yang

et al. 2024

DMSO

View full text Add to dashboard Cite

Purpose Diabetic nephropathy (DN), a major complication of diabetes mellitus, significantly impacts global health. Identifying individuals at risk of developing DN is crucial for early intervention and improving patient outcomes. This study aims to develop and validate a machine learning-based predictive model using integrated biomarkers. Methods A cross-sectional analysis was conducted on a baseline dataset involving 2184 participants without DN, categorized based on their development of DN over a follow-up period of 36 months: DN (n=1270) and Non-DN (n=914). Various demographic and clinical parameters were analyzed. The findings were validated using an independent dataset comprising 468 participants, with 273 developing DN and 195 remaining as Non-DN over the follow-up period. Machine learning algorithms, alongside traditional descriptive statistics and logistic regression were used for statistical analyses. Results Elevated levels of serum creatinine, urea, and reduced eGFR, alongside an increased prevalence of retinopathy and peripheral neuropathy, were prominently observed in those who developed DN. Validation on the independent dataset further confirmed the model’s robustness and consistency. The SVM model demonstrated superior performance in the training set (AUC=0.79, F1-score=0.74) and testing set (AUC=0.83, F1-score=0.82), outperforming other models. Significant predictors of DN included serum creatinine, eGFR, presence of diabetic retinopathy, and peripheral neuropathy. Conclusion Integrating machine learning algorithms with clinical and biomarker data at baseline offers a promising avenue for identifying individuals at risk of developing diabetic nephropathy in type 2 diabetes patients over a 36-month period.

show abstract

“…This is directly related to AH, type 2 DM, and OB, and the increasing prevalence of these diseases among young and middle-aged people is of particular concern. Unfortunately, these comorbid diseases lead to an increased risk of cardiovascular complications, the development of which causes disability and premature death in people of active working age [1][2][3].…”

mentioning

confidence: 99%

Dependence of Cardiotrophin-1 on Biochemical and Hormonal Factors in Patients With Comorbid Pathology: Arterial Hypertension, Diabetes Mellitus Type 2 and Obesity

Дунаєва

Біловол

2023

PEP

View full text Add to dashboard Cite

The prevalence of arterial hypertension, type 2 diabetes mellitus (type 2 DM), and obesity is constantly increasing worldwide. Today, a complex of factors, which primarily include chronic emotional stress, pandemics of infectious diseases, military conflicts, have led to a significant increase in chronic non-communicable diseases. The aim of the study. To determine the dependence of Cardiotrophin-1 on a number of biochemical and hormonal indicators in patients with arterial hypertension, type 2 DM, and obesity, representatives of the Ukrainian population. Materials and methods. The study included 211 patients aged 49 to 65 years, who were divided into groups depending on the pathology: patients with arterial hypertension – 49 persons, Group I; patients with arterial hypertension in combination with class 1 obesity – 54 persons, Group 2; patients with arterial hypertension in combination with type 2 DM – 57 persons, Group 3; patients with arterial hypertension, type 2 DM, class 1 obesity – 51 persons, Group 4; as well as 20 persons – the Control group. Determination of the content of Cardiotrophin-1, catestatin, leptin, cystatin C, neutrophil gelatinase-associated lipocalin (NGAL), N-terminal brain natriuretic peptide (NT-proBNP), 25-OH of common vitamin D (Vitamin D3), blood levels was carried out by enzyme immunoassay on Labline-90 analyzer (Austria), using commercial test systems manufactured by FineTest (ELISA, China), BT LAB (ELISA, China), DBC (ELISA, China), Elabscience (ELISA, Canada), Monobind Inc. (ELISA, USA). Statistical data analysis was performed, using the statistical software package Statistica, 12 (Stat Soft Inc, USA), Microsoft Office Excel 2013. Data are shown as mean (M) and standard deviations (δ). An error of less than 5% was considered to be significant (p<0.05). Stepwise regression analysis was used to determine the extent of exposure of the studied indicators to the CTF-1 level, with its effectiveness assessed by one-way analysis of variance (ANOVA). Results. Thus, the study indicates that comorbid patients with arterial hypertension, type 2 DM, and obesity are predicted to develop complications from the cardiovascular system and Cardiotrophin-1 is a marker of their development. In the examined patients as a whole, the level of Cardiotrophin-1 is closely related to the peptide-hormonal complex: catestatin, leptin, cystatin C, brain natriuretic peptide, and lipocalin associated with neutrophil gelatinase. Conclusions: The serum concentration of Cardiotrophin-1 in patients with arterial hypertension increases significantly in a progression with the rate of accession of comorbid pathology and its severity. The Cardiotrophin-1 level in patients with comorbid pathology is affected by catestatin, leptin, cystatin C, NT-pro BNP, as well as the level of triglycerides, HDL-C, creatinine, and BMI. Cardiotrophin-1 can be considered as a universal biomarker for the development and progression of cardiovascular disorders in patients with comorbid pathology of arterial hypertension, type 2 DM, and obesity.

show abstract

L'hypertension artérielle masquée chez les diabétiques de type 2 : Prévalence, facteurs associés et retentissement cardiovasculaire

Cited by 8 publications

References 14 publications

Management of the ‘wicked’ combination of heart failure and chronic kidney disease in the patient with diabetes

Management of the ‘wicked’ combination of heart failure and chronic kidney disease in the patient with diabetes

Machine Learning-Based Predictive Modeling of Diabetic Nephropathy in Type 2 Diabetes Using Integrated Biomarkers: A Single-Center Retrospective Study

Dependence of Cardiotrophin-1 on Biochemical and Hormonal Factors in Patients With Comorbid Pathology: Arterial Hypertension, Diabetes Mellitus Type 2 and Obesity

Contact Info

Product

Resources

About